Tests a lung rehabilitation program in people with advanced lung cancer
Tests a breathing and exercise program in adults with advanced non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients
Key facts
- Where
- Mexico City, MexicoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with advanced non-small-cell lung cancer who can get chemotherapy or tyrosine kinase inhibitors. It tests a pulmonary rehabilitation program.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed advanced non-small-cell lung cancer, in good general condition (ECOG 0-1), with life expectancy of more than 12 weeks.
- Earlier treatment
- Must be able to receive treatment with chemotherapy or tyrosine kinase inhibitors. A recent electrocardiogram must show no arrhythmia.
Main reasons for not taking part
- Brain metastasis that causes symptoms
- Pain that is not controlled (Visual Analog Scale above 5)
- High blood pressure that is not controlled (above 140/100mmHg)
- Regular moderate to intense exercise at least 3 days a week
- Not living in Mexico City or unable to attend therapy sessions
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT02978521, who can take part
Where in Mexico
- Instituto Nacional de CancerologiaMexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Nacional de Cancerologia de Mexico
- Trial code
- NCT02978521
- Record updated
- 8 April 2026
- Original description
Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC.Read full original descriptionShow less
Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed With Non-small-cell Advanced Cancer
Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC.
Pulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue and improve exercise tolerance in patients with LC undergoing curative surgery. However, few studies have focused on the efficacy of PR on patients with advanced cancer undergoing palliative care with chemotherapy or targeted therapies.
Inclusion: Confirmed diagnosis of advanced non-small-cell lung cancer; Good performance status (ECOG 0-1); Life expectancy >12 weeks; Eligible to receive treatment with chemotherapy or tyrosinkinase inhibitors; Recent electrocardiogram without evidence of arrythmia.
Exclusion: Not residents of Mexico City or unable to attend to therapy sessions; Uncontrolled hypertension (>140/100mmHg); Symptomatic brain metastasis; Uncontrolled pain (Visual Analog Scale >5); Practice of regular moderate to intense physical activity at least 3 day/week.